4.2.16 A trough level of any protease inhibitor (other than a boosting dose of ritonavir) or non-nucleoside reverse transcriptase inhibitor included in the subject's antiretroviral regimen at screening that is below the lower limit of the steady-state trough level range observed in published studies, according to Table 2, below.